Bronx Transthyretin Amyloid Cardiomyopathy Database

Clinical Trial
Study Details
Enrollment
476
Primary Completion
Status
ACTIVE NOT RECRUITING
Study Completion
Study ID #
NCT06257485
Study Start
Study Type
Observational
Summary

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a commonly undiagnosed and potentially fatal disease. Contemporary studies on this condition often underrepresent the female gender and diverse patient populations. This registry retrospectively evaluated patients referred for 99mTc-pyrophosphate (PYP) Single Photon Emission Computed Tomography (SPECT) between 2014 and 2023 at Montefiore-Einstein in the Bronx. The patient population is racially and ethnically diverse and with a high proportion of females. Demographic, clinical (e.g. comorbidities), laboratory, echocardiographic, hospitalization, and mortality data were collected for each patient.

Study Overview
Participation Criteria
Eligibility Criteria

Inclusion Criteria:

* All adult patients referred for PYP SPECT at Montefiore Medical Center between 2014 and 2023

Exclusion Criteria:

* Did not have a transthoracic echocardiogram in our medical records

Eligibility Minimum Age
18 Years
Sexes Eligible for Study
ALL
Eligibility Std Ages
Adult
Older Adult
Study Population

All adult patients referred for PYP SPECT at Montefiore Medical Center between 2014 and 2023 who had a transthoracic echocardiogram in our medical records.